cp wire

CP Wire Articles

Coherus BioSciences Re-Submits BLA for Neulasta (Pegfilgrastim) Biosimilar Candidate
  • Coherus received a complete response letter from th FDA in June 2017
  • Competitors Mylan and Biocon received a CRL in October of 2017
  • Neulasta has generated $20 billion in... read more
Thu, 05/3/18 - 02:45 pm
CytRx Names Industry Veteran as President and COO

CytRx Corporation (NASDAQ: CYTR), announced on 5/3/18 that its Board of Directors has approved the appointment of Eric L. Curtis, MBA, to the Company's executive management team, as President and... read more

Thu, 05/3/18 - 12:25 pm
Hemostemix Announces First Patient Treated in Stem Cell Trial for Critical Limb Ischemia

Hemostemix Inc. (TSX VENTURE:HEM) announced on 5/3/18 that it has treated its first patient under its continuing Phase II Clinical Trial for critical limb ischemia (“CLI”).  The first patient was... read more

Thu, 05/3/18 - 12:11 pm
Alnylam and FDA Agree on Primary Endpoint for Lumasiran in Primary Hyperoxaluria Type 1 Study


Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), announced on 5/3/18 that the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on a pivotal study design for... read more

Thu, 05/3/18 - 11:12 am
EMA Validates Bristol-Myers Squibb’s Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer



Bristol-Myers Squibb Company (NYSE: BMY) announced on 5/3/18 that the European Medicines Agency (EMA) validated a type II variation application for the Opdivo (nivolumab) plus Yervoy(... read more

Thu, 05/3/18 - 09:24 am

Pages